1	Effectiveness of SGLT2 inhibitor therapy in treatment of Heart failure: A Meta-Analysis
2 3	Sarvinoz Albalushi ^{*1} , Azmaeen Zarif ^{*,†,2,3} , Suheyla Karaduman ⁴ , Khoa Tran ⁵ , Alesia Talpeka ^{6,7}
4	
5	¹ University of Debrecan, Debrecen, Egyetem tér 1, 4032 Hungary
6 7	² University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, Cambridgeshire, CB2 0SP, United Kingdom
8 9	³ Gonville & Caius College, University of Cambridge, Trinity Street, Cambridge, Cambridgeshire, CB2 1TA, United Kingdom
10	⁴ Uludag University Medical School, Özlüce, Uludağ Ünv., 16285 Nilüfer/Bursa, Türkiye
11 12	⁵ Pham Ngoc Thach University of Medicine, 2 Đ. Dương Quang Trung, Phường 12, Quận 10, Thành phố Hồ Chí Minh, Vietnam
13	⁶ Belarusian State Medical University, Prospekt Dzerzhinskogo 83, Minsk 220116, Belarus
14	⁷ Minsk City Clinical Oncology Center, 1st City Clinical Hospital, Nezavisimosti Svenue, 64, Minsk 220040
15	
16	[†] Corresponding author:
17	Azmaeen Zarif
18	Gonville & Caius College
19	University of Cambridge
20	Trinity Street
21	Cambridge
22	Cambridgeshire
23	CB2 1TA
24	United Kingdom
25	Email: az397@cam.ac.uk

- 26
- 27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Abstract

Aim: We conducted a meta-analysis on the effectiveness of sodium-glucose co-transporter 2 (SGLT2)
 inhibitors in heart failure (HF) patients with preserved (HFpEF) and reduced (HFrEF) ejection fraction.

31 Methods: A comprehensive search of several databases for placebo-controlled randomised controlled trials of 32 SGLT2 inhibitors from inception to September 30 2022, limited to English language and excluding animal 33 studies, was conducted. The databases included Medline, Scopus, Cochrane Central, and ClinicalTrials.gov. 34 Randomised controlled studies were chosen if they included HF patients and reported at least one of the 35 predetermined outcomes. Hazard ratios (HRs) or risk ratios were pooled together with the appropriate 95% 36 confidence intervals using a random-effect model. Fourteen trials met the inclusion criteria, with 42 409 HF 37 patients participating (N = 21 678 in the SGLT2 inhibitor arms and N = 20 731 in the placebo arms).

38 Results: SGLT2 inhibitors significantly reduced the composite of HF hospitalisation or cardiovascular death

39 [HR: 0.75 (0.71–0.79); P < 0.001; $I^2 = 0\%$], total hospitalisations for heart failure [HR: 0.70 (0.66– 40 0.75); P < 0.001; $I^2 = 0\%$], and reduced the occurrence of cardiovascular death [HR: 0.86 (0.81–0.92); P <

41 0.001; $I^2 = 43\%$]. Sub-group analysis was conducted based on HF status at baseline, EF, diabetes status at

11 olooi,1 lovoji buo group unarjois was conducted based on 111 status a basenne, 21, diacetes status a

42 baseline, and sex. SGLT2 inhibitors significantly reduced the composite heart failure hospitalisation and 43 cardiovascular death for all the subgroups except for patients with HFpEF at baseline [HR: 0.87 (0.74–

44 1.03); P = 0.11; $I^2 = 60\%$] and no diabetes status at baseline [HR: 0.92 (0.73–1.16); P = 0.50; $I^2 = 78\%$].

Conclusions: In patients with HF, SGLT2 inhibitors may significantly improve clinical outcomes, including
all-cause and cardiovascular mortality. In this meta-analysis, SGLT2 inhibitors did not show a reduction in
composite heart failure in patients with heart failure with preserved ejection fraction at baseline.

48

49 Keywords: sodium-glucose co-transporter 2 inhibitors, heart failure with preserved ejection fraction,

50 heart failure with reduced ejection fraction, hospitalization, mortality

- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

61 Effectiveness of SGLT2 inhibitor therapy in treatment of Heart failure: A Meta-Analysis

62

63 Introduction

64 Sodium-glucose co-transporter inhibitor (SGLT2i) has emerged to be effective in the treatment of heart failure 65 with preserved (HFpEF) and reduced ejection fraction (HFrEF). Recently, The American Heart Association (AHA), The American College of Cardiology (ACC), and Heart Failure Society of America (HSFA) published 66 guidelines for the management of heart failure in which SGLT2i was introduced as a novel therapeutic drug 67 68 class (1,2). Careful evaluation of new evidence and comprehensive literature research encompassing clinical 69 trials, research studies, and review papers revealed its efficacy and benefit in treating HFrEF to reduce 70 hospitalisation. Since an earlier meta-analysis (3), covering seven major trials, was published in 2020, there 71 have been seven more major trials that have been conducted (4-10). Therefore, we conducted this meta-analysis 72 to provide a revised estimation of the efficacy of SGLT2i in heart failure patients.

73

Method 74

75

76 Data sources and search strategy

77 Cochrane and PRISMA (Preferred Reporting Items for Systematic review and Meta-Analyses) guidelines were 78 utilised (11,12). A comprehensive search of several databases for placebo-controlled randomised controlled 79 trials of SGLT2 inhibitors from inception to September 30 2022, limited to English language and excluding 80 animal studies, was conducted. The databases included: Medline, Scopus, Cochrane Central, and 81 ClinicalTrials.gov. In order to find relevant results, the following keywords and their MeSH terms were used: (Sodium Glucose Transporter 2 Inhibitors OR sodium-glucose co-transporter inhibitor OR SGLT-2 Inhibitors 82 83 OR SGLT 2 Inhibitors OR SGLT2 Inhibitors OR Gliflozins OR tofogliflozin OR sotagliflozin OR 84 empagliflozin OR canagliflozin OR dapagliflozin OR ertugliflozin OR luseugliflozin OR ipragliflozin OR remogliflozin OR sergliflozin AND Cardiac Failure OR Myocardial Failure OR Congestive Heart Failure OR 85 86 heart failure OR Heart Decompensation). See Table S1 for the specific search strategies utilised for the 87 respective databases. For the purpose of finding any pertinent studies that may have been missed during the 88 search, reference lists of the included trials were carefully checked.

89

91 Selection criteria for the study and eligibility

92 Articles were chosen for inclusion if they complied with all of the following eligibility requirements: HF

93 patients were included, the studies (i) compared SGLT2 inhibitors to placebo, (ii) randomised control trial

94 (RCT) or post hoc assessments of RCTs, and (iii) contained at least one of the specified outcomes of interest.

95

96 Data extraction, outcomes of interest, and quality evaluation

97 The composite of cardiovascular death or HF hospitalisation was the major outcome of interest. Other results

98 of interest were: (i) composite of total HF hospitalisation and cardiovascular death; (ii) cardiovascular death;

(iii) death with HF at baseline; (iv) all-cause death; (v) renal composite outcome among all patients; and (vi)

100 renal composite outcome based on HF status at baseline. A sub-group analysis based on baseline HF status,

101 ejection fraction, baseline diabetes status, and baseline sex was also conducted.

102

99

103 Statistical analysis

104 All statistical analyses were performed using RevMan (Review Manager Version 5.4), Copenhagen: The 105 Nordic Cochrane Centre, (The Cochrane Collaboration, 2014). For four time-to-event clinical outcomes, 106 including Composite of total HF hospitalisation or cardiovascular death, hospitalisation for heart failure, 107 cardiovascular death, all-cause mortality, and composite renal outcome, hazard ratios and accompanying 95% 108 confidence intervals were retrieved. Hazard ratios were log transformed and pooled using either fixed effect 109 or random effect model. Using the DerSimonian-Liard random-effect model, we accounted for the expected 110 heterogeneity in the study design, difference in the intervention drug and its usage, and variance in 111 operationalisation of outcome. Where heterogeneity was less than 50%, a fixed-effect model was used instead. 112 We applied an inverse variance method to assign the respective weighting of included studies. In a random-113 effect model, the weight of a study is equal to the inverse of the variance of the study effect and allows the 114 study outcomes to vary according to a normal distribution. However, in a fixed-effect model, the weight given 115 to each study in the analysis varies according to the sample size.

A subgroup analysis was conducted based on sex, diabetes status at baseline, heart failure at baseline (this cohort included all patients with HFrEF, HFpEF, and patients with unknown type of heart failure), and for patients with HFrEF, and HFpEF.

119 Subgroup differences were analysed using χ^2 test while statistical heterogeneity was measured via I^2 statistical

120 testing. We used post-hoc analysis statistics of trials for subgroup analysis. Publication bias was analysed using

121 funnel plot. Statistical significance was defined as a P-value ≤ 0.05 .

123 Result

124 Study Characteristics

125 The procedure for searching and choosing studies is summarised in the PRISMA flow chart (Supplementary 126 Materials, Figure S1). Data were gathered from 14 RCTs that assessed SGLT2 inhibitors. 42 409 HF patients 127 participated in the total trial population for this meta-analysis (N = 21 678 in the SGLT2 inhibitor arms and N 128 = 20 731 in the placebo arms). Of those, 18 838 participants made up the HFrEF subgroup (N = 9475 in the 129 SGLT2 arms and N = 9363 in the placebo arms). There were 8542 participants in the HFpEF subgroup (N = 130 4441 in the SGLT2 arm and N = 4101 in the placebo arm). The HF type for the remaining individuals were 131 not indicated in their respective studies.

132

133 Table 1. Characteristics of selected studies.

Bibliom	etric properties	r i i i i i i i i i i i i i i i i i i i		Sample Characterit	iscs	
Author	Study design	N	Age	Gender	Sample	NYHA functional classification. %
Anker et al.(2021)	double-blind, placebo- controlled trial,	N=3730 patients Diabetes Intervention: 927 Control: 929 No Diabetes Intervention: 936 Control: 938	N=3730 patients Diabetes Intervention: 66.8±10.0 Control: 66.6±10.3 No Diabetes Intervention: 67.6±11.6 Control: 66.3±12.0	N-3730 patients Diabetes Intervention (F): 210 (22.7) Control: 218 (23.5) No Diabetes Intervention (F): 227 (24.3) Control: 238 (25.4)	Class II–IV heart failure and a left ventricular ejection fraction ≤40%	Diabetes Intervention/Control II: 657 (70.9) 668 (71.9) III: 265 (28.6) 6253 (27.2) IV: 5 (0.5)/8 (0.9) No Diabetes Intervention/Control Er42 (79.3) 733 (78.1) II: 190 (20.3) 202 (21.5) III: 4 (0.4)/3 (0.3)
Packer et al.(2021)	double-blind randomized trial	N= 3,730	N=3730 patients Patients without recent volume overload Intervention: 66.7 ± 10.8 Control: 66.4 ± 11.2 Patients with recent volume overload Intervention: 67.9 ± 10.8 Control: 66.6 ± 11.3	N=3730 patients Patients without recent volume overload Intervention (F): 282 (24.8) Control: 280 (25.2) Patients with recent volume overload For the state of the state of the state of the state Control: 174 (23.1)	New York Heart Association (NYHA) functional class II to IV heart failure and an ejection fraction ≤40%	N=3730 patients Patients without recent volume overload Intervention: 243 (21.3) Control: 221 (19.9) Patients with recent volume overload Intervention: 221 (30.6) Control: 244 (32.4)
Voors et al. (2022)	multinational randomized trial	N=530 Placebo: 265 Intervention: 265	median age was 71 years (interquartile range, 61–78 years) Intervention: 71 (62–78) Control: 70 (59–78)	34% were women Intervention (F): 86 (32.5) Control (F): 93 (35.1)	primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction	Intervention/Control 1: 8 (3.0)/6 (2.3) 11: 95 (35.8)/91 (34.3) 111: 134 (50.6)/145 (54.7) IV: 26 (9.8)/23 (8.7)
Sarraju et al.(2021)	multicenter, double- blind, randomized trial	4401 participants Participants with HF Intervention: 329 Control: 323 Participants without HF Intervention: 1873 Control: 1876	4401 participants Participants with HF Intervention: 64.8 (8.1) Control: 65.5 (8.1) Participants without HF Intervention: 62.5 (9.3) Control: 62.8	4401 participants Participants with HF Intervention (F): 124 (37.7%) Control: 133 (41.2%) Participants without HF Intervention(F): 638 (34.1%) Control: 599 (31.9%)	participants with hemoglobin A1c between 6.5% to 12.0%, an estimated glomerular filtration rate of 30 to <90 mL per minute per 1.73 m2 of body surface area, and elevated abuminuria (urinary abumin:creatinine ratio, >300-5000 mg/g)	
Szarek et al.,(2021)	Randomized controlled trial	1222 Intervention: 608 Control: 614	Intervention: 69 (63-76) Control: 70 (64-76)	Intervention (F): 198 (32.6) Control (F): 214 (34.9)	Patients With Type 2 Diabetes Post Worsening Heart Failure	
Anker et al.(2021)	Randomized controlled trial	N=5899 Intervention: 2997 Placebo: 2991	Intervention: 71.8+ 9.3 Control: 71.9+ 9.6	Intervention (F): 1338(44.6) Control (F): 1338(44.7)		Intervention/Control 1: 3(0,1)!(<0.1) II: 2432(81.1)/2451(81.9) III: 552(18.4/531(17.8) IV: 10(0.3/58(0.3)
Packer et al.(2021)	Double blind randomized controlled trial	N=5988			class II through IV heart failure with an ejection fraction of >40%	
Packer et al.(2020)	Double blind randomized controlled trial	Intervention: 1863 Control: 1867	Intervention: 67.2 (10.8) Control: 66.5 (11.2)	Intervention (F): 437 (23.5) Control: 456 (24.4)	Patients with class II, III, or IV heart failure and an ejection fraction of 40% or less	Intervention/Control II: 75.1/75.0 III: 24.4/24.4 IV: 0.5/0.6
McMurray et al. (2019)	placebo-controlled trial	N=4744 Intervention: 2373 Control:2371	Intervention: 66-2 (11-0) Control: 66.5 (10.8)	Intervention (F): 564 (23-8%) Control: 545 (23-0%)	patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less	Intervention/Control II: 1606 (67-7%)/1597 (67-4%) III: 747 (31-5%)/751 (31-7%) IV: 20 (0-8%)/23 (1-0%)
Radhom et al. (2018)	Randomized controlled trial	N=10142 Intervention: 803 Control: 658	Intervention: 64.1 (8.3) Control: 63.4 (8.3)	Intevrention (F): 346 (43.1) Control: 302 (45.9)	participants with type 2 diabetes mellitus and high cardiovascular risk	
Radhom et al. (2018)	Randomized controlled trial	N=10142 Intervention: 803 Control: 658	Intervention: 64.1 (8.3) Control: 63.4 (8.3)	Intevrention (F): 346 (43.1) Control: 302 (45.9)	participants with type 2 diabetes mellitus and high cardiovascular risk	
Bhatt et al (2020)	multicenter, double-blind trial	N=1222 Intervention: 608 Comtrol: 614	Intervention: 69 (63–76) Control: 70 (64–76)	Intervention (F): 198 (32.6) Control: 214 (34.9)	patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure	
Cosentino et al (2020)	double-blind, placebo-controlled trial,	Intervention: 1286 Control: 672	Intervetnion: 64.2 (7.9) Control: 64.7 (7.8)	Intervention (F): 395 (30.7) Control: 229 (34.1)	patients with type 2 diabetes mellitus and atherosclerotic cardiovascular (CV) disease	Intervention/Control II: 62.0/67.1 III: 5.5/3.8 IV: 0.0/0.0
Fitchett et al (2016)	double-blind, placebo-controlled trial,	Patients with heart failure Intervention: 462 Control: 244 Patietns without heart failure Intervention: 4225 Control: 2089	Patients with heart failure Intervention: 64.5 (8.8) Control: 64.5 (8.9) Patietns without heart failure Intervention: 63.0 (8.5) Control: 63.1 (8.8)	Patients with heart failure Intervention (M): 320 (69.3) Control: 175 (71.7) Patietns without heart failure Intervention (M): 3016 (71.4) Control: 1505 (72.0)	patients with type 2 diabetes and high cardiovascular risk	
Wiviott (2018)	randomized, double-blind, multinational, placebo-controlled	Intervention: 8582 Control: 8578	Intervention: 63.9±6.8 Control: 64.0±6.8	Intervention (F): 63.9±6.8 Control: 3251 (37.9)	type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease	

- 135
- 136
- 137
- 138

Table 2. Baseline patient characteristics in selected studies.

			Baseline characteristics				
Author	Intervention	Control	HFpEF	HFrEF	Diabetes	Hospitalization for heart failure	Composit hospitalization and cardiac death
Anker et al.(2021)	empagliflozin 10 mg daily	placebo in addition to recommended therapy			1856 (50%) and 1268 (34%) had prediabetes	N=3730 patients Diabetes Intervention: 316 (34.1) Control: 314 (33.8) No Diabetes Intervention: 261 (27.9) Control: 260 (27.7)	Intervention: 361/1863 (19.4) Control: 462/1867 (24.7) HR: 0.75 (0.65, 0.86)
Packer et al.(2021)	empagliflozin 10 mg daily	placebo in addition to recommended therapy				N=3730 patients Patients without recent volume overload Intervention: 293 (25.7) Control: 282 (25.4) Patients with recent volume overload Intervention: 2283 (39.1) Control: 291 (38.6)	
Voors et al. (2022)	empagliflozin 10 mg daily	placebo			Intervention: 124 (46.8) Control: 116 (43.8)		Intervention: 34/265 Control: 49/265 HR: 0.69 (0.45–1.08)
Sarraju et al.(2021)	canagliflozin 100 mg	Placebo			4401 participants Participants with HF Intervention (F): 14.8 (8.6) Control: 15.1 (8.5) Participants without HF Intervention(F): 15.7 (8.7) Control: 16.2 (8.6)		HR: 0.70 (0.59, 0.82) Overall events: \$85/4401 Intervention: 43.2/1000 Control; 61.2/1000
Szarek et al.,(2021)	200 mg of sotagliflozin	Placebo			Intervention: 198 (32.6) Control: 214 (34.9)		
Anker et al.(2021)	empagliflozin 10 mg daily	Placebo			Intervention (F): 1466(48.9) Control(F): 1472(49.2)	Intervention(F): 699 (23.3) Control (F): 670 (22.4)	Intervention: 415(13.8)/2997 Control: 511(17.1)/2991
Packer et al.(2021)	empagliflozin (10 mg once daily)	Placebo					Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432/2997 versus 546/2991 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% (1, 0.67–0.87]; P<0.0001).
Packer et al.(2020)	empagliflozin (10 mg once daily)	Placebo			Intervention: 927 (49.8) Control: 929 (49.8)	Intervention: 577 (31.0) Control: 574 (30.7)	Intervention: 361 (19.4)/1863 (30.9%) Control: 462 (24.7)/1867 (40.3%) HR: 0.75 (0.65 to 0.86)
McMurray et al. (2019)	dapagliflozin (at a dose of 10 mg once daily	Placebo			Intervention: 1075 (45·3%) Control: 1064 (44·9%)	Intevrention: 1124 (47·4%) Control: 1127 (47·5%)	Intervention: 567/2373(23.9%) Control: 724/2371 (31.3%) HR: 0.75 (0.65-0.88)
Radhom et al. (2018)	canagliflozin 300 mg, canagliflozin 100 mg	Control					Intervention: 35.4/1000 Control: 56.8/1000 HR: 0.61 (0.46-0.80)
Radhom et al. (2018)	canagliflozin 300 mg, canagliflozin 100 mg	Control					Intervention: 35.4/1000 Control: 56.8/1000 HR: 0.61 (0.46-0.80)
Bhatt et al (2020)	200 mg of sotagliflozin once daily	Placebo	Intevrention: 127 (20.9) Control: 129 (21.0)	Intervention: 481 (79.1) Control: 85 (79.0)			Intervention: 245 (51.0) Control: 355 (76.3) HR: 0.67 (0.52 to 0.85)
Cosentino et al (2020)	once-daily ertugliflozin 5 mg, 15 mg	Placebo	Intervention: 680 (52.9) Control: 327 (48.6)	Intervention: 319 (24.8) Control: 159 (23.7)			All patients Intervention: 139/5499 Control: 99/2747 HR: 0.70 (0.54-0.90)
Fitchett et al (2016)	empagliflozin 10 mg, empagliflozin 25 mg	Placebo					All patients: Intervention: 265/4687 patients (5.7%) Control: 198/2333 patients (8.5%) HR: 0.66 (95% confidence interval, 95% CI: 0.55-0.79
Wiviott (2018)	10 mg of dapagliflozin daily	Placebo					Intervention: 417 (4.9)/8582 Control: 496 (5.8)/8578 HR: 0.83 (0.73–0.95)

Table 3. Summary clinical outcomes reported from selected studies.

		Outcom	e	
Author	Hospitalization for heart failure	Cardiac death	All cause death	Renal composite
Anker et al.(2021)	Intervention: 388/1863 Control: 553/1867 HR: 0.70 (0.58, 0.85)	Intervention: 187/1863 (10.0) Control: 202/1867 (10.8) HR: 0.92 (0.75, 1.12)		Intervention: 30/1863 (1.6) Control: 58/1867 (3.1) HR: 0.50 (0.32, 0.77) HR: 0.50 (0.32, 0.77)
Packer et al.(2021)				
Voors et al. (2022)	Intervention (14 (5.3)/265) Control (12 (4.5)/265) HR: 1.179 (0.534–2.601)	Intervention: 11 (4.2)/265 Control: 22 (8.3)/265		
Sarraju et al.(2021)	Overall events: 230/4401 Intervention: 15.7/1000 Control: 25.3/1000 HR: 0.61 (0.47, 0.80)	Overall events: 486/4401 Intervention: 38.7/1000 Control: 48.7/1000 HR: 0.80 (0.67, 0.95)	Overall events: 369/4401 Intervention: 29.0/1000 Control: 35.0/1000 HR: 0.83 (0.68, 1.02)	Overall events: 377/4401 Intervention: 27.0/1000 Control: 40.0/1000 HR: 0.66 (0.53, 0.81)
Szarek et al.,(2021)	HR: 0.76 (0.63–0.93) Intervention: 97.6 (83.4–111.8)/608 Control: 126.6 (107.6–145.6)/614			
Anker et al.(2021)	Intervention:259(8.6)/2997 control: 352(11.8)/2991	intervention : 219(7.3)/ 2997 Control: 244(8.2)/ 2991	Intervention: 422(14.1)/ 2997 Control: 427(14.3)/2991	Intervention: 108(3.6)/ 2997 control: 112(3.7)/ 2991
Packer et al.(2021)	Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care (hazard ratio, 0.71 [95% CI, 0.52–0.96]; P=0.028) [(86/2997 versus 117/2991 patients [empagliflozin versus placebo, respectively]			Compared with patients in the placebo group, fewer patients in the empagliflozin group reported outpatient intensification of diuretics (482/2997 versus 610/2991; hazard ratio, 0.76 [95% CI, 0.67–0.86]; P<0.0001),
Packer et al.(2020)	Intervention:388/1863 Control: 5531867 HR: 0.70 (0.58 to 0.85)	Intervention: 187/1863 (10.0%) Control: 202/1867 (10.8%) HR: 0.92 (0.77-1.12)	Intervention: 249/1863 (13.4%) Control: 266/1867 (14.2%) HR: 0.92 (0.77-1.10)	Intervention:30 (1.6)/1863 Control: 58 (3.1)/1867 HR: 0.50 (0.32 to 0.77)
McMurray et al. (2019)	Intervention: 231/2373(9.7%) Control: 318/2371 (13.4%) HR: 0.70 (0.59-0.83)	Intervention: 227/2373(9.6%) Control: 273/2371 (11.5%) HR: 0.82 (0.69-0.98)	Intervention: 276/2373 (11.6%) Control: 329/2371 (13.9%) HR: 0.83 (0.71-0.97)	Intervention: 28/2373(1.2%) Control: 39/2371 (1.6%) HR: 0.71 (0.44-1.16)
Radhom et al. (2018)	Intervention: 14.1/1000 Control: 28.1/1000 HR: 0.51 (0.33-0.78)	Intervention: 24.3/1000 Control: 31.6/1000 HR: 0.72 (0.51-1.02)	Intervention: 29.2/1000 Control: 38.7/1000 HR: 0.70 (0.51-0.96)	Intervention: 6.8/1000 Control: 11.0/1000 HR: 0.67 (0.30-1.51)
Radhom et al. (2018)	Intervention: 14.1/1000 Control: 28.1/1000 HR: 0.51 (0.33-0.78)	Intervention: 24.3/1000 Control: 31.6/1000 HR: 0.72 (0.51-1.02)	Intervention: 29.2/1000 Control: 38.7/1000 HR: 0.70 (0.51-0.96)	Intervention: 6.8/1000 Control: 11.0/1000 HR: 0.67 (0.30-1.51)
Bhatt et al (2020)	Intervention: 194 (40.4) Control: 297 (63.9) HR: 0.64 (0.49 to 0.83)	Intervention: 51 (10.6) Control: 58 (12.5) HR: 0.84 (0.58 to 1.22)	Intevrention: 65 (13.5) Control: 76 (16.3) HR: 0.82 (0.59 to 1.14)	
Cosentino et al (2020)		· · · · ·		
Fitchett et al (2016)	All patients: Intervention: 126/4687 patients (2.7%) Control: 95/2333 patients (4.1%) HR: 0.65 (95% Cl: 0.50–0.85)	All patients: Intervention: 172/4687 patients Control: 137/2333 patients HR: 0.62 (95% CI: 0.49–0.77)	All patients: Intervention: 269/4687 patients Control: 194/2333 patients HR: 0.68 (95% Cl: 0.57–0.82)	
Wiviott (2018)	Intervention: 212 (2.5)/8582 Control: 286 (3.3)/8578 HR: 0.73 (0.61–0.88)	Intervention: 245 (2.9)/8582 Control: 249 (2.9)/8578 HR: 0.93 (0.82–1.04)	Intervention: 529 (6.2)/8582 Control: 570 (6.6)/8578 HR: 0.98 (0.82–1.17)	

159
 Table 4.
 Sub-group analysis clinical outcomes.
 ARB: angiotensin receptor blocker; ARNI: angiotensin receptor/neprilysin inhibitor; ACE: angiotensin-converting enzyme; CRT-P: cardiac resynchronisation therapy 160 161 pacemaker; eGFR: estimated glomerular filtration rate; ICD: implantable cardiac defibrillator; LVEF: left 162 ventricular ejection fraction; NT-proBNP: N-terminal pro-B type natriuretic peptide; NYHA: New York Heart 163 Association; SD: standard deviation; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure

164 with reduced ejection fraction. Information is presented as n (%), mean (SD), or median (interquartile range).

					166
Author	Composit hospitalization and cardiac death	Hospitalization for heart failure	Cardiac death	All cause death	Renal composite
Anker et al.(2021)	Diabetes Intervention:200/927 (21.6) Control: 265/929 (28.5) HR: 0.72 (0.60, 0.87) No Diabetes Intervention: 161/936 (17.2) Control: 197/938 (21.0) HR: 0.78 (0.64, 0.97	Diabetes Intervention: 221/927 Control: 337/929 0.085 HR: 0.65 (0.50, 0.85) No Diabetes Intervention: 167/936 0.0111:016/938 Control: 216/938 HR: 0.76 (0.57, 1.01)	Diabetes Intervention: 104/927 (11.2) Control: 113/929 (12.2) HR:0.29 (0.71, 1.20) No Diabetes Intervention: 83/936 (8.9) Control: 80/938 (6.5) HR: 0.92 (0.68, 1.24)		Diabetes Intervention: 22/927 (2.4) Control: 39/929 (4.2) HR:0.53 (0.31, 0.90) No Diabetes Intervention: 8/936 (0.9) Control: 19/938 (2.0) HR: 0.42 (0.19, 0.97)
Packer et al.(2021)	Patients without recent volume overload intervention: 182 (16.0) Control: 246 (22.2) HR: 0.71 (0.58-0.98h), p. 0.0004 Patients with recent volume overload intervention: 179 (24.8) Control: 214 (28.4) HR: 0.81 (0.66-0.99h), p. 0.035	Patients without recent volume overload Intervention: 181 Control: 275 HR: 0.60 (0.47-0.78), p = 0.0002 Patients with recent volume overload Intervention: 207 Control: 274 HR: 0.84 (0.63-1.12), p = 0.24	Patients without recent volume overload Intervention: 93 (8.2) Control: 104 (9.4) HR: 0.89 (0.67-1.77), p. = 0.40 Patients with recent volume overload Intervention: 94 (13.0) Control: 98 (13.0) HR: 0.98 (0.72-1.27), p. = 0.76		Patients without recent volume overload intervention: 15 (1.3) Control: 28 (2.5) HR: 0.51 (0.27-0.95), $p = 0.034$ Patients with recent volume overload intervention: 15 (2.1) Control: 30 (4.0) HR: 0.49 (0.26-0.92), $p = 0.025$
Voors et al. (2022)	Gender: Male Intervention: 179 Control: 172 WR: 1.39 (1.06-1.92) Female: Intervention: 86 Control: 93 WR: 1.27 (0.88-1.83) Diabetes Control: 174 Win ratio: 1.47 (1.07-0.20) No Diabetes Intervention: 141 Control: 149 HR: 1.39 (0.97-1.73) Reduced ejection fraction Intervention: 182 Control: 12 HR: 1.35 (1.04-1.75) Preserved ejection fraction Intervention: 76 Control: 17 HR: 1.39 (0.95-2.03)				
Sarraju et al.(2021)	HF Intervention: 62.4/1000 Control: 65.5/1000 HR: 0.69 (0.61, 1.31) No HF Intervention: 39.9/1000 Control: 60.5/1000 HR: 0.66 (0.55-0.79)	FrF Intervention: 67.5/1000 Control: 7805/1000 HR: 0.81 (0.57, 1.17) No HF Intervention: 11.7/1000 Control: 25.1000 HR: 0.54 (0.39-0.75)	FeF Intervention: 62.1/1000 Control: 65.1/1000 HR: 0.3/1 (0.62, 1.34) No HF Intervention: 34.7/1000 Control: 45.9/1000 HR: 0.76 (0.62-0.93)	FHF Intervention: 51.9/1000 Control: 54, 1/1000 HR: 0.33 (0.61, 1.41) No HF Intervention: 25.1/1000 Control: 3.81/1000 HR: 0.79 (0.63-1.00)	FHF Intervention: 25.2/1000 Control: 33.4/1000 HR: 0.69 (0.39, 1.21) No HF Intervention: 27.3/1000 Control: 41.6/1000 HR: 0.65 (0.52-0.81)
Szarek et al. (2021)					
Anker et al.(2021)	Gender: Male Intervention: 253/1659 Control: 297/1653 HR: 0.81 (0.69-0.96) Female: Intervention: 162/1338 Control: 214/1338 HR: 0.75 (0.61-0.92) Diabetes Intervention: 239/1466 Control: 239/1472 HR: 0.79 (0.61-0.92) HR: 0.79 (0.61-0.92) HR: 0.79 (0.61-0.94) HR: 0.79 (0.61-0.94) HR: 0.79 (0.61-0.95) Reduced ejection fraction Intervention: 145/995 Control: 239/988 HR: 0.71 (0.57-0.88) Preserved ejection fraction intervention: 132/974 Control: 132/974				
Packer et al.(2021) Packer et al.(2020)	Gender: Male Intervention: 294/1426 Control: 353/1411 HR: 0.80 (0.66-0.93) Female: Intervention: 307/1809 Control: 406/1826 HR: 0.73 (0.68-0.85) Diabetes Intervention: 215/1075 Control: 271/1064 HR: 0.72 (0.60-0.87) No Diabetes Intervention: 161/936 Control: 197/938 HR: 0.75 (0.63-0.93) Reduced ejection fraction Intervention: 80/699 Control: 115/724 HR: 0.70 (0.53-0.93) Preserved ejection fraction Intervention: 108/526 Control: 97/475 HR: 0.39 (0.76-1.31)				

McMurray et al. (2019)	Gender: Male Intervention: 294/1426 Control: 333/1411 HR: 0.30 (0.68–0.93) Fernale: Intervention: 67/437 Control: 109/456 HR: 0.59 (0.44–0.80) Diabetes Intervention: 200/927 Control: 265/929 HR: 0.72 (0.60–0.87) NO Diabetes Intervention: 71/1298 Control: 21/11/307 HR: 0.73 (0.60–0.81) Reduced ejection fraction Intervention: 100/1193 Control: 15/1179 HR: 0.53 (0.40–0.60) Preserved ejection fraction Intervention: 347/1191 HR: 0.73 (0.66–0.92)				
Radhom et al. (2018) Radhom et al					
(2018)					
Cosentino et el	Gender: Male Intervention: 55.7/100 Control: 89.3/100 HR: 0.62 (0.47–0.82) Fermale: Intervention: 41.9/100 Control: 52.0 HR: 0.80 (0.51–1.25) Reduced ejection fraction Intervention: 56.9/100 Control: 7.9.9/100 HR: 0.72 (0.56–0.94) Preserved ejection fraction intervention: 30.6/100 Control: 64.0/100 HR: 0.48 (0.27–0.86)	HE			
(2020)		PF Intervention: 69/1286 Control: 55/671 HR: 0.63 (0.440.30) No HF Intervention: 70/4213 Control: 44/2075 HR: 0.79 (0.54, 1.15) Reduced Ejection Fraction Intervention: 37/638 Control: 37/638 Control: 37/631 HR: 0.48 (0.30, 0.76) Preserved ejection fraction Intervention: 37/321 HR: 0.48 (0.58, 1.29) HR: 0.86 (0.58, 1.29) Letter and the second sec			
Fitchett et al (2016)	Patients with Heart Failure Intervention: 75/462 Control:49/244 HR:0.72 (0.50-1.04) Patients without heart failure Intervention: 190/4225 Control: 149/2089 HR: 0.63 (0.51-0.78)	Patients with Heart Failure Intervention: 48/462 Control:30/244 HR:0.75 (0.48-1.19) Patients without heart failure Intervention: 78/4225 Control: 65/2089 HR: 0.59 (0.43-0.82)	Patients with Heart Failure Intervention: 38/462 Control:27/244 HR:0.71 (0.43-1.16) Patients without heart failure Intervention: 134/4225 Control: 110/2089 HR: 0.60 (0.47-0.77)	Patients with Heart Failure Intervention: 56/462 Control:33/244 HR:0.79 (0.52-1.20) Patients without heart failure Intervention: 213/4225 Control: 159/2089 HR: 0.66 (0.51-0.81)	
Wiviott (2018)	Patients with Heart Failure Intervention: 142/852 Control: 172/872 HR-0.79 (0.63–0.59) Patients without heart failure Intervention: 275/7730 Control: 324/7706 HR: 0.84 (0.72–0.99)				

186 Results

187 Composite of HF hospitalization or cardiac death

188 Results of meta-analysis indicated that SGLT2 inhibitors significantly reduced the composite of HF hospitalisation 189 or cardiovascular death [HR: 0.75 (0.71–0.79); P < 0.001; $I^2 = 0\%$] (Figure 1). Sub-group analysis was conducted 190 to based on HF status at baseline, ejection fraction, diabetes status at baseline, and gender. SGLT2 inhibitors 191 significantly reduced the composite heart failure hospitalisation and cardiac death for all the subgroups except for 192 patients with HFpEF at baseline [HR: 0.87 (0.74-1.03); P = 0.11; I² = 60%] and no diabetes status at baseline [HR: 193 0.92 (0.73-1.16); P = 0.50; I² = 78%]. Moreover, there was significant difference between patients with and without heart failure at baseline [$\chi 2 = 0.06$, df = 1; P = 0.81), I²= 0%], patients with reduced and preserved ejection 194 195 fraction [$\gamma 2 = 0.08$, df = 1; P = 0.37), I2= 0%], patients with and without diabetes status at baseline [$\gamma 2 = 0.62$, df = 1; P = 0.43), $I^2 = 0\%$], and men and women [$\chi 2 = 0.34$, df = 1; P = 0.56), $I^2 = 0\%$]. Sub-group analyses are presented 196 197 in Figure 2.

198

				Hazard Ratio		Hazard Ratio		
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% Cl		IV, Fixed, 95%	CI	
Anker et al., 2021 (a)	-0.2908	0.0714	12.1%	0.75 [0.65, 0.86]		+		
Anker et al., 2021 (b)	-0.2382	0.0678	13.4%	0.79 [0.69, 0.90]		-		
Bhatt et al., 2020	-0.4082	0.1254	3.9%	0.66 [0.52, 0.85]				
Cosentino et al., 2020	-0.3608	0.1303	3.6%	0.70 [0.54, 0.90]				
Fitchett et al., 2016	-0.4168	0.0924	7.2%	0.66 [0.55, 0.79]		-		
McMurray et al., 2019	-0.2793	0.0773	10.3%	0.76 [0.65, 0.88]		+		
Packer et al., 2020	-0.2908	0.0714	12.1%	0.75 [0.65, 0.86]		+		
Packer et al., 2021 (b)	-0.2699	0.0666	13.9%	0.76 [0.67, 0.87]		•		
Sarraju et al., 2021	-0.363	0.084	8.7%	0.70 [0.59, 0.82]		-		
Voors er al., 2022	-0.3608	0.2233	1.2%	0.70 [0.45, 1.08]				
Wiviott et al., 2018	-0.183	0.0672	13.6%	0.83 [0.73, 0.95]		-		
Total (95% CI)			100.0%	0.75 [0.71, 0.79]		•		
Heterogeneity: Chi ² = 7.1	5, df = 10 (P = 0.71)	; I² = 0%					- 10	100
Test for overall effect: Z =	= 11.63 (P < 0.00001	0.01 0.1	SGLT2 Place	bo	100			

199 Figure 1. Forest plot displaying effect size for composite score of HF hospitalisation or cardiac death among all

200 patients

201

A

				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.3 HF at baseline					
Fitchett et al., 2016	-1.4783	0.7742	0.7%	0.23 [0.05, 1.04]	
Radhom et al., 2018	-0.4998	0.1412	11.4%	0.61 [0.46, 0.80]	-
Sarraju et al., 2021	-0.1121	0.195	7.5%	0.89 [0.61, 1.31]	
Wiviott et al., 2018	-0.236	0.1153	14.1%	0.79 [0.63, 0.99]	-
Subtotal (95% CI)			33.7%	0.72 [0.56, 0.92]	•
Heterogeneity: Tau² = I	0.03; Chi² = 5.52, df =	= 3 (P = 0	.14); I² = -	46%	
Test for overall effect: 2	Z = 2.61 (P = 0.009)				
4 4 4 1 - 115 - 4 1 15-	_				
1.1.4 NO HE at baseline	e				
Fitchett et al., 2016	-0.4609	0.1084	14.9%	0.63 [0.51, 0.78]	-
Radhom et al., 2018	-0.1351	0.0987	16.1%	0.87 [0.72, 1.06]	-
Sarraju et al., 2021	-0.4168	0.0924	16.9%	0.66 [0.55, 0.79]	+
Wiviott et al., 2018	-0.1693	0.0812	18.4%	0.84 [0.72, 0.99]	
Subtotal (95% CI)			66.3%	0.75 [0.64, 0.88]	•
Heterogeneity: Tau ² = 1	0.02; Chi² = 8.99, df =	= 3 (P = 0	.03); I ² = I	67%	
Test for overall effect: 2	Z = 3.55 (P = 0.0004)				
Total (DEW CI)			100.0%	0.74 [0.65, 0.94]	
Total (95% CI)			100.0%	0.74 [0.65, 0.84]	•
Heterogeneity: Tau ² =	0.02; Chi ^z = 14.65, df	= 7 (P =	0.04); l² =	= 52%	
Test for overall effect: 2	Z = 4.75 (P < 0.00001)			SGLT2 Placebo
Test for subgroup diffe	erences: Chi ² = 0.06,	df = 1 (P	= 0.81), P	²=0%	

B

				Hazard Ratio		Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% Cl		IV, Random, 95% Cl	
1.1.3 Reduced ejection	fraction						
Anker et al., 2021 (b)	-0.345	0.1108	9.3%	0.71 [0.57, 0.88]		-	
Bhatt et al., 2020	-0.3208	0.1321	8.4%	0.73 [0.56, 0.94]			
McMurray et al., 2019	-0.4682	0.1251	8.7%	0.63 [0.49, 0.80]		-	
Packer et al., 2020	-0.3537	0.1434	8.0%	0.70 [0.53, 0.93]			
Packer et al., 2021 (a)	-0.3478	0.1005	9.8%	0.71 [0.58, 0.86]		-	
Voors er al., 2022	0.2994	0.1328	8.4%	1.35 [1.04, 1.75]		.	
Subtotal (95% CI)			52.7%	0.77 [0.63, 0.95]		•	
Heterogeneity: Tau ² = 0.	05; Chi ² = 22.44, df =	: 5 (P = 0	.0004); I ^z	= 78%			
Test for overall effect: Z	= 2.45 (P = 0.01)						
1.1.4 Preserved ejectio	n fraction						
Anker et al., 2021 (b)	-0.1379	0.119	9.0%	0.87 [0.69, 1.10]		-+	
Bhatt et al., 2020	-0.7301	0.2955	3.7%	0.48 [0.27, 0.86]			
McMurray et al., 2019	-0.2345	0.0771	10.8%	0.79 [0.68, 0.92]		-	
Packer et al., 2020	-0.0022	0.1389	8.2%	1.00 [0.76, 1.31]		+	
Packer et al., 2021 (a)	-0.2128	0.1034	9.7%	0.81 [0.66, 0.99]		-	
Voors er al., 2022	0.3284	0.1937	6.1%	1.39 [0.95, 2.03]			
Subtotal (95% CI)			47.3%	0.87 [0.74, 1.03]		•	
Heterogeneity: Tau ² = 0.	02; Chi² = 12.60, df =	: 5 (P = 0	.03); I ² = 6	50%			
Test for overall effect: Z	= 1.61 (P = 0.11)						
Total (95% CI)			100.0%	0.82 [0.72, 0.93]		•	
Heterogeneity: Tau ² = 0.	04; Chi ^z = 37.54, df =	÷11 (P ≺	0.0001);1	l² = 71%		1	10 100
Test for overall effect: Z	= 3.01 (P = 0.003)				0.01	SGLT2 Placebo	.0 .00
Test for subgroup differ	ences: Chi² = 0.80, d	f=1 (P=	0.37), l ² =	= 0%			

208 С

				Hazard Ratio	Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
1.1.3 Diabetes at base	eline					
Anker et al., 2021 (a)	-0.325	0.0948	11.0%	0.72 [0.60, 0.87]	+	
Anker et al., 2021 (b)	-0.2312	0.0864	11.4%	0.79 [0.67, 0.94]	+	
McMurray et al., 2019	-0.325	0.0948	11.0%	0.72 [0.60, 0.87]	+	
Packer et al., 2020	-0.325	0.0948	11.0%	0.72 [0.60, 0.87]	+	
Voors er al., 2022	0.3854	0.1621	8.0%	1.47 [1.07, 2.02]		
Subtotal (95% CI)			52.5 %	0.82 [0.68, 0.99]	◆	
Heterogeneity: Tau ² = (0.03; Chi ^z = 17.28, df	= 4 (P = 1	0.002); I ^z :	= 77%		
Test for overall effect: Z	Z = 2.09 (P = 0.04)					
1.1.4 No Diabetes at b	aseline					
Anker et al., 2021 (a)	-0.2384	0.1061	10.5%	0.79 [0.64, 0.97]	-	
Anker et al., 2021 (b)	-0.2488	0.1008	10.7%	0.78 [0.64, 0.95]	+	
McMurray et al., 2019	-0.3193	0.0977	10.9%	0.73 [0.60, 0.88]	+	
Packer et al., 2020	0.2588	0.1476	8.6%	1.30 [0.97, 1.73]		
Voors er al., 2022	0.3284	0.1937	6.8%	1.39 [0.95, 2.03]		
Subtotal (95% CI)			47.5%	0.92 [0.73, 1.16]	◆	
Heterogeneity: Tau ² = (0.05; Chi² = 18.39, df	= 4 (P = 1	0.001); I ²:	= 78%		
Test for overall effect: 2	Z = 0.68 (P = 0.50)	-				
Total (95% CI)			100.0%	0.87 [0.75, 0.99]	•	
Heterogeneity: Tau² = (0.04; Chi ^z = 37.25, df	= 9 (P < I	0.0001); I	²= 76%		ł.
Test for overall effect: 2	Z = 2.04 (P = 0.04)				0.01 0.1 1 10 100 SGLT2 Placebo	,
Test for subaroup diffe	rences: Chi ² = 0.62.	df = 1 (P =	= 0.43), I ²	= 0%	SOLIZ FIALEDO	

209

210 D

				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.3 Male					
Anker et al., 2021 (b)	-0.2059	0.0842	12.5%	0.81 [0.69, 0.96]	+
Bhatt et al., 2020	-0.4767	0.142	9.0%	0.62 [0.47, 0.82]	
McMurray et al., 2019	-0.2291	0.0799	12.7%	0.80 [0.68, 0.93]	+
Packer et al., 2020	-0.2291	0.0799	12.7%	0.80 [0.68, 0.93]	+
Voors er al., 2022	0.3553	0.1515	8.5%	1.43 [1.06, 1.92]	
Subtotal (95% CI)			55.4%	0.84 [0.70, 1.01]	◆
Heterogeneity: Tau ² = 0).03; Chi ² = 17.50, df	= 4 (P = I	0.002); <mark>I</mark> ≧:	= 77%	
Test for overall effect: Z	(= 1.84 (P = 0.07)				
1.1.4 Female					
Anker et al., 2021 (b)	-0.2888	0.1048	11.2%	0.75 [0.61, 0.92]	+
Bhatt et al., 2020	-0.2251	0.2287	5.3%	0.80 [0.51, 1.25]	
McMurray et al., 2019	-0.5221	0.1525	8.4%	0.59 [0.44, 0.80]	
Packer et al., 2020	-0.3123	0.0764	12.9%	0.73 [0.63, 0.85]	+
Voors er al., 2022	0.2382	0.1868	6.8%	1.27 [0.88, 1.83]	.+
Subtotal (95% CI)			44.6%	0.78 [0.64, 0.94]	•
Heterogeneity: Tau² = 0).03; Chi ² = 10.46, df	= 4 (P = I	0.03); I ² =	62%	
Test for overall effect: Z	(= 2.58 (P = 0.01)				
Total (95% CI)			100.0%	0.81 [0.71, 0.92]	•
Heterogeneity: Tau² = 0).03; Chi ² = 29.45, df	= 9 (P = I	0.0005); P	²= 69%	
Test for overall effect: Z	(= 3.23 (P = 0.001)				SGLT2 Placebo
Test for subgroup diffe	rences: Chi ² = 0.34, (df = 1 (P :	= 0.56), I ^z	'= 0%	55E12 1186666

211

212 Figure 2. Sub-group analysis for composite score of HF hospitalisation or cardiac death based on HF status at 213 baseline (A), HFrEF & HFpEF (B), diabetes status at baseline (C), and gender (D).

- Hospitalization for heart failure (HHF)
- SGLT2 inhibitors resulted in a significant reduction in total hospitalisations for heart failure [HR: 0.70 (0.66-
- 0.75); P < 0.001; $I^2 = 0\%$] (Figure 3). Sub-group analysis was conducted for patients with and without heart failure
- at baseline and results indicated that SGLT2 inhibitors reduced hospitalisation for heart failure among both group
- with no significant difference between them [$\chi 2 = 0.02$, df = 1; P = 0.89), I²= 0%] (Figure 4).

				Hazard Ratio		Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% Cl		IV, Fixed, 95% Cl	
Anker et al., 2021 (a)	-0.3536	0.0975	11.5%	0.70 [0.58, 0.85]		+	
Anker et al., 2021 (b)	-0.3486	0.0828	15.9%	0.71 [0.60, 0.83]		•	
Bhatt et al., 2020	-0.4498	0.1344	6.1%	0.64 [0.49, 0.83]			
Fitchett et al., 2016	-0.4278	0.1354	6.0%	0.65 [0.50, 0.85]			
McMurray et al., 2019	-0.357	0.0871	14.4%	0.70 [0.59, 0.83]		-	
Packer et al., 2020	-0.3536	0.0975	11.5%	0.70 [0.58, 0.85]		-	
Packer et al., 2021 (b)	-0.3474	0.1564	4.5%	0.71 [0.52, 0.96]			
Sarraju et al., 2021	-0.4891	0.1357	5.9%	0.61 [0.47, 0.80]			
Szarek et al., 2021	-0.2673	0.0994	11.1%	0.77 [0.63, 0.93]		-	
Voors er al., 2022	0.1603	0.4057	0.7%	1.17 [0.53, 2.60]			
Wiviott et al., 2018	-0.3111	0.0935	12.5%	0.73 [0.61, 0.88]		-	
Total (95% CI)			100.0%	0.70 [0.66, 0.75]		•	
Heterogeneity: Chi ² = 4.3	8, df = 10 (P = 0.93)	; I² = 0%					10 100
Test for overall effect: Z =	: 10.68 (P < 0.00001			0.01 0.1	SGLT2 Placebo	10 100	
Packer et al., 2020 Packer et al., 2021 (b) Sarraju et al., 2021 Szarek et al., 2021 Voors er al., 2022 Wiviott et al., 2018 Total (95% CI) Heterogeneity: Chi ² = 4.3 Test for overall effect: Z =	-0.3336 -0.3474 -0.4891 -0.2673 0.1603 -0.3111 18, df= 10 (P = 0.93) : 10.68 (P < 0.00001	0.0975 0.1564 0.1357 0.0994 0.4057 0.0935 ; I ² = 0%	4.5% 5.9% 11.1% 0.7% 12.5%	0.70 [0.58, 0.85] 0.71 [0.52, 0.96] 0.61 [0.47, 0.80] 0.77 [0.63, 0.93] 1.17 [0.53, 2.60] 0.73 [0.61, 0.88] 0.70 [0.66, 0.75]	HHHHHHHH	SGLT2 Placebo	

Figure 3. Forest plot displaying effect size for HHF.

				Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
1.2.1 HF at baseline					
Cosentino et al., 2020	-0.4632	0.1826	12.7%	0.63 [0.44, 0.90]	
Fitchett et al., 2016	-0.28	0.2316	7.9%	0.76 [0.48, 1.19]	
Radhom et al., 2018	-0.6786	0.2194	8.8%	0.51 [0.33, 0.78]	
Sarraju et al., 2021 Subtotal (95% CI)	-0.2026	0.1835	12.6% 42.1 %	0.82 [0.57, 1.17] 0.67 [0.55, 0.82]	•
Heterogeneity: Chi ² = 3.1	16, df = 3 (P = 0.37);	l²=5%			
Test for overall effect: Z =	= 3.94 (P < 0.0001)				
1.2.2 No HF at baseline					
Cosentino et al., 2020	-0.2382	0.1928	11.4%	0.79 [0.54, 1.15]	
Fitchett et al., 2016	-0.5212	0.1647	15.7%	0.59 [0.43, 0.82]	
Radhom et al., 2018	-0.238	0.1654	15.5%	0.79 [0.57, 1.09]	
Sarraju et al., 2021	-0.6146	0.1668	15.3%	0.54 [0.39, 0.75]	
Subtotal (95% CI)			57.9%	0.66 [0.56, 0.78]	•
Heterogeneity: Chi ² = 3.8	33, df = 3 (P = 0.28);	≥ =22%			
Test for overall effect: Z =	= 4.83 (P < 0.00001)				
Total (95% CI)			100.0%	0.67 [0.59, 0.76]	•
Heterogeneity: Chi ² = 7.0	01, df = 7 (P = 0.43);				
Test for overall effect: Z =	= 6.23 (P < 0.00001)	0.01 0.1 1 10 100 SGLT2 Placebo			
Test for subgroup differe	ences: Chi² = 0.02, d	30E12 Flatebo			

Figure 4. Sub-group analysis for HHF based on HF status at baseline.

Cardiac Death

SGLT2 inhibitors significantly reduced the occurrence of cardiovascular death among participants [HR: 0.86 (0.81-

0.92); P < 0.001; $I^2 = 43\%$] (Figure 5). The findings were consistent in patients with and without heart failure at

baseline [$\chi 2 = 0.01$, df = 1; P = 0.97), I²= 0%] depicted in sub-group analysis Figure 6.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.10.23295313; this version posted September 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

				Hazard Ratio		Hazard Ratio	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% Cl		IV, Fixed, 95% Cl	
Anker et al., 2021 (a)	-0.0872	0.1023	10.1%	0.92 [0.75, 1.12]			
Anker et al., 2021 (b)	-0.0941	0.092	12.4%	0.91 [0.76, 1.09]		-	
Bhatt et al., 2020	-0.1729	0.1897	2.9%	0.84 [0.58, 1.22]		-+	
Fitchett et al., 2016	-0.4874	0.1153	7.9%	0.61 [0.49, 0.77]		-	
McMurray et al., 2019	-0.1956	0.0895	13.2%	0.82 [0.69, 0.98]		-	
Packer et al., 2020	-0.074	0.0956	11.5%	0.93 [0.77, 1.12]		+	
Sarraju et al., 2021	-0.2259	0.0891	13.3%	0.80 [0.67, 0.95]		-	
Wiviott et al., 2018	-0.0796	0.0606	28.7%	0.92 [0.82, 1.04]		•	
Total (95% CI)			100.0%	0.86 [0.81, 0.92]		•	
Heterogeneity: Chi² = 12.29, df = 7 (P = 0.09); l² = 43%							10 100
Test for overall effect: Z	= 4.66 (P < 0.00001))			0.01 0.1	SGLT2 Placebo	10 100





Figure 6. Sub-group analysis for cardiac death based on HF status at baseline.

254

255

257 All-cause mortality

- 258 SGLT2 inhibitors significantly reduced all-cause mortality among participants [HR: 0.87 (0.78-0.96); P =
- 259 0.04; $I^2 = 55\%$] (Figure 7). The findings were consistent in patients with and without heart failure at baseline [$\gamma 2 =$
- 260 0.08, df = 1; P = 0.78), $I^2 = 0\%$] as demonstrated by sub-group analysis (Figure 8).

261



262 Figure 7. Forest plot displaying effect size for all-cause mortality among all patients.

263

				Hazard Ratio	Hazard R	atio
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 9	5% CI
1.4.1 HF at baseline						
Fitchett et al., 2016	-0.2358	0.2133	6.3%	0.79 [0.52, 1.20]		
Radhom et al., 2018	-0.3571	0.1614	11.0%	0.70 [0.51, 0.96]		
Sarraju et al., 2021 Subtotal (95% Cl)	-0.0754	0.2138	6.3% 23.5 %	0.93 [0.61, 1.41] 0.78 [0.63, 0.97]	•	
Heterogeneity: Chi ² = 1	.11, df = 2 (P = 0.57)	; I² = 0%				
Test for overall effect: 2	I = 2.26 (P = 0.02)					
1.4.2 No HF at baseline	9					
Fitchett et al., 2016	-0.442	0.118	20.6%	0.64 [0.51, 0.81]		
Radhom et al., 2018	-0.0721	0.09	35.3%	0.93 [0.78, 1.11]	+	
Sarraju et al., 2021 Subtotal (95% Cl)	-0.231	0.1179	20.6% 76.5 %	0.79 (0.63, 1.00) 0.81 (0.72, 0.91)	•	
Heterogeneity: Chi ² = 6	6.24, df = 2 (P = 0.04)	; I ² = 689	6			
Test for overall effect: Z	(= 3.50 (P = 0.0005)					
Total (95% Cl)			100.0%	0.80 [0.72, 0.89]	•	
Heterogeneity: Chi ² = 7	.43, df = 5 (P = 0.19)	; I Z = 339	6			10 100
Test for overall effect: Z = 4.16 (P < 0.0001)					SGLT2 PI	acebo
Test for subgroup differences: $Chi^2 = 0.08$, $df = 1$ (P = 0.78), $I^2 = 0.06$					00612 11	00000

264

265 Figure 8. Sub-group analysis for all-cause mortality based on HF status at baseline.

266

Renal composite outcome

- SGLT2 inhibitor reduced the occurrence of the composite renal endpoint [HR: 0.6\70 (0.-0.83); P < 0.001; $I^2 = 55\%$] (Figure 9). This finding was consistent in both post-hoc analyses for patients with and
- without heart failure [$\chi 2 = 0.26$, df = 1; P = 0.61), I²= 0%] (Figure 10).

				Hazard Ratio		Hazard Ratio		
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Random, 95% Cl		IV, Random, 95% C	1	
Anker et al., 2021 (a)	-0.7004	0.224	10.4%	0.50 [0.32, 0.77]				
Anker et al., 2021 (b)	-0.0498	0.1352	18.7%	0.95 [0.73, 1.24]		-		
McMurray et al., 2019	-0.3363	0.2473	9.1%	0.71 [0.44, 1.16]				
Packer et al., 2020	-0.7004	0.224	10.4%	0.50 [0.32, 0.77]				
Packer et al., 2021 (b)	-0.2757	0.0637	29.0%	0.76 [0.67, 0.86]		•		
Sarraju et al., 2021	-0.4228	0.1082	22.4%	0.66 [0.53, 0.81]		-		
Total (95% CI)			100.0%	0.70 [0.59, 0.83]		•		
Heterogeneity: Tau ² = 0.02; Chi ² = 11.15, df = 5 (P = 0.05); l ² = 55%						1	10 10	1
Test for overall effect: Z = 4.15 (P < 0.0001)					0.01 0.1	SGLT2 Placebo	10 10	

Figure 9. Forest plot displaying effect size for renal composite outcome among all patients.

				Hazard Ratio	Hazard Ratio			
Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
1.5.1 HF at baseline								
Radhom et al., 2018	-0.3959	0.4123	2.8%	0.67 [0.30, 1.51]				
Sarraju et al., 2021	-0.4228	0.1082	40.4%	0.66 [0.53, 0.81]	.			
Subtotal (95% CI)			43.2%	0.66 [0.53, 0.81]	•			
Heterogeneity: Chi ² = 0).00, df = 1 (P = 0.95)); I² = 0%						
Test for overall effect: Z	Z = 4.02 (P < 0.0001)							
1.5.2 No HF at baseline	9							
Radhom et al., 2018	-0.6614	0.1698	16.4%	0.52 [0.37, 0.72]				
Sarraju et al., 2021	-0.4228	0.1082	40.4%	0.66 [0.53, 0.81]	.			
Subtotal (95% CI)			56.8 %	0.61 [0.51, 0.73]	•			
Heterogeneity: Chi ² = 1	Heterogeneity: Chi ² = 1.40, df = 1 (P = 0.24); l ² = 29%							
Test for overall effect: Z	Z = 5.39 (P < 0.00001)						
T-4-1/05% OD			400.00	0.001055.0701	•			
Total (95% CI)			100.0%	0.63 [0.55, 0.72]	•			
Heterogeneity: Chi ² = 1.67, df = 3 (P = 0.64); i ² = 0%								
Test for overall effect: Z = 6.71 (P < 0.00001)					SGLT2 Placebo			
Test for subgroup diffe	rences: Chi ² = 0.26,	df = 1 (P	= 0.61), P	²=0%				

Figure 10. Sub-group analysis for renal composite outcome based on HF status at baseline.

282 Assessing publication bias

- 283 In the funnel plot (Figure 11), the data points represent the RCTs included in the study. They all lie within the 95%
- 284 CI. The data points are predominantly located in the apex of the 95% CI with some predominantly located on the
- 285 left. The depicted asymmetry indicates there might have been some bias in the study that might overestimate the
- intervention's effect and this should be kept in mind when used by clinicians as a reference.
- 287
- 288



- **Figure 11.** Funnel plot to assess publication bias.
- 290
- 291
- 292
- 293
- 294
- 295
- - -
- 296
- 297
- 298
- 299
- _//
- 300

301 Discussion

302

303 SGLT2 inhibitors significantly decreased the risk of cardiovascular mortality, HF hospitalisation, all-cause 304 mortality, and renal outcomes in this extensive investigation involving over 42 000 HF patients. These results 305 were true when the HFrEF population was examined alone and when the patients were divided into groups 306 based on their diabetes status. However, this tendency was not observed in the HFpEF subgroup. Due to the 307 limited and inconsistent availability of data, this discovery should be viewed as exploratory rather than 308 conclusive. SGLT2 inhibitors were not shown to increase the probability of major adverse events or 309 discontinuation owing to adverse events compared to placebo.

All HF-specific studies revealed statistically significant decreases in the composite of cardiovascular death or total HF hospitalisation. These trials' meta-analysis shows a substantial decrease in cardiovascular and allcause mortality. The reduction in mortality in HF patients was further supported by findings from post-hoc analyses of cardiovascular outcome studies. We report that the reduction in mortality advantage is true independent of DM status.

The funnel plot was used to assess publication bias, where all the selected RCT lie within the 95% confidence interval but predominantly towards the left side which might indicate presence of bias to some extend. Finally, despite the fact that methodological heterogeneity was accounted for using a random-effects model, some variations between studies may make interpretation more difficult. This includes the use of various SGLT2 inhibitor subtypes, varying sex ratios, variations in background therapies, baseline risk severity of patients included, and variances in safety and renal endpoint definitions among studies.

The results of this meta-analysis demonstrate that SGLT2 inhibitors significantly lower mortality, renal outcomes, and HF hospitalisations. These results were true for individuals with HFrEF as well as for diabetics and non-diabetics. In patients with HFpEF, there was no upward trend toward improvement. Our results confirm that all HF patients, regardless of diabetes status, may benefit from SGLT2 inhibitors; however, the benefits for patients with preserved ejection fraction are still debatable; we require more RCT to study it more precisely. The results of this study can be useful for clinicians in making decision whether to incorporate SGLT2 inhibitors in their treatment plan.

- 328
- 329
- 330
- - -
- 331
- 332
- 333

334	Declaratio	ns
-----	------------	----

- *Competing interests*
- 337 The authors declare that they have no competing interests.
- 339 Funding
- 340 None.
- *Authors' contributions*
- 343 SA conceptualised the meta-analysis and prepared the initial draft of the manuscript. AZ supported
- 344 writing of the draft and oversaw its critical review and editing. *Both SA and AZ contributed equally
- 345 to this work as co-first-authors. SK, KT, and AT undertook the literature search and helped prepare

the manuscript draft. All authors read and approved the final manuscript.

- 348 Acknowledgements
- 349 We would like to express our gratitude to Ms Qurat ul Ain for her support with the statistical analysis.

361 References

- 362 [1] Kunzmann, K., 2022. New ACC, AHA, HFSA guidelines recommend SGLT-2 inhibitors for symptomatic
- 363 heart failure. HCPLive. Available at: https://www.hcplive.com/view/acc-aha-hfsa-guidelines-sglt-2-
- 364 inhibitors-symptomatic-heart-failure [Accessed August 21, 2022].

[2] Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol.* 2022 May, 79 (17) e263–e421.https://doi.org/10.1016/j.jacc.2021.12.012

- 367 [3] Butler, J., Usman, M. S., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos,
 368 G., Coats, A. J. S., and Anker, S. D. (2020) Efficacy and safety of SGLT2 inhibitors in heart failure:
 369 systematic review and meta-analysis. *ESC Heart*370 *Failure*, 7: 3298–3309. https://doi.org/10.1002/ehf2.13169.
- [4] Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S., ... & EMPEROR-Reduced Trial
 Committees and Investigators. (2021). Effect of empagliflozin on cardiovascular and renal outcomes in
 patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced
 trial. *Circulation*, 143(4), 337-349.
- 375

[5] Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., ... & EMPEROR-Reduced
Trial Committees and Investigators. (2021). Empagliflozin in patients with heart failure, reduced ejection
fraction, and volume overload: EMPEROR-reduced trial. *Journal of the American College of Cardiology*, 77(11), 1381-1392.

- 380
- [6] Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., ... & Ponikowski,
 P. (2022). The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational
 randomized trial. *Nature medicine*, 28(3), 568-574.
- 384

[7] Sarraju, A., Li, J., Cannon, C. P., Chang, T. I., Agarwal, R., Bakris, G., ... & Mahaffey, K. W. (2021).
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and
chronic kidney disease according to history of heart failure: results from the CREDENCE trial. *American Heart Journal*, 233, 141-148.

389

diabetes and worsening heart failure: a randomized trial. *Annals of internal medicine*, *174*(8), 1065-1072.

^[8] Szarek, M., Bhatt, D. L., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., ... & SOLOIST-WHF
committees and investigators. (2021). Effect of sotagliflozin on total hospitalizations in patients with type 2

- 393 [9] Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & Packer, M. (2021).
- Empagliflozin in heart failure with a preserved ejection fraction. *New England Journal of Medicine*, 385(16),
 1451-1461.
- 396
- 397 [10] Packer, M., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Pocock, S. J., ... & EMPEROR-Preserved
- 398 Trial Study Group. (2021). Effect of empagliflozin on worsening heart failure events in patients with heart
- 399 failure and preserved ejection fraction: EMPEROR-Preserved trial. *Circulation*, *144*(16), 1284-1294.
- 400
- 401 [11] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ,
- Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies
 that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
- 404
- 405 [12] Higgins JPTGS. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane406 Collaboration. 2011.

407 [13] Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks
408 L, Sterne JAC. The Cochrane Collaboration's tool for assessing risk of bias in randomised
409 trials. *BMJ* 2011; 343: d5928.

410

[14] Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon
CP, Perkovic V, Jardine MJ, Neal B. Sodium-glucose cotransporter 2 inhibition for the prevention of
cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *J Am Heart Assoc* 2020; 9: e014908.

- 415
- 416
- 417
- 418
- 419
- 420
- 421
- 422
- 423